Colorectal cancer: A model for epigenetic tumorigenesis

Gut

Volumn 56, Issue 1, 2007, Pages 140-148

  Wong, J J L ^b   Hawkins, N J ^b   Ward, R L ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APC; DNA; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN P16INK4A; UVOMORULIN; VON HIPPEL LINDAU PROTEIN; WNT PROTEIN;

CARCINOGENESIS; CHROMATIN STRUCTURE; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; CPG ISLAND; DISEASE COURSE; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MICROSATELLITE INSTABILITY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSCRIPTION REGULATION;

CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HISTONES; HUMANS; MICROSATELLITE INSTABILITY; MODELS, GENETIC;

EID: 33846008439     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.088799     Document Type: Review

References (140)

1. Holliday R. Epigenetics comes of age in the twentyfirst century. J Genet 2002;81:1-4.
2. Wu CT, Morris JR. Genes, genetics, and epigenetics: a correspondence. Science 2001;293:1103-5.
3. Nature Milestones [cited 2006 20 April]; Available from: www.nature.com/milestones/milecancer/timeline.html S7-23 (accessed 27 Oct 2006).
4. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
5. Zilberman D, Cao X, Jacobsen SE. ARGONAUTE4 control of locus-specific siRNA accumulation and DNA and histone methylation. Science 2003;299:716-19.
6. Volpe TA, Kidner C, Hall IM, et al. Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science 2002;297:1833-7.
7. Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 2004;431:211-17.
8. Holliday R. DNA methylation and epigenetic defects in carcinogenesis. Mutat Res 1987;181:215-17.
9. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457- 63.
10. Ogryzko VV, Schlitz RL, Russanova V, et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996;87:953-9.
11. Fuks F, Burgers WA, Brehm A, et al. DNA melhyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000;24:88-91.
12. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 2000;25:269-77.
13. Ng HH, Jeppesen P, Bird A. Active repression of methylated genes by the chromosomal protein MBD1. Mol Cell Biol 2000;20:1394-406.
14. Saito M, Ishikawa F. The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J Biol Chem 2002;277:35434-9.
15. Kondo Y, Issa J-PJ. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 2004;23:29-39.
16. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-80.
17. Lieb JD, Clarke ND. Control of transcription through intragenic patterns of nucleosome composition. Cell 2005;123:1187-90.
18. Ramsahoye BH, Biniszkiewicz D, Lyko F, et al. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci USA 2000;97:5237-42.
19. Ehrlich M, Gama-Sosa MA, Huang LH, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 1982;10:2709-21.
20. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA 1993;90:11995-9.
21. Plass C, Soloway PD. DNA methylation, imprinting and cancer. Eur J Hum Genet 2002;10:6-16.
22. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6:597-610.
23. Wilkins JF. Genomic imprinting and methylation: epigenetic canalization and conflict. Trends Genet 2005;21:356-65.
24. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006;31:89-97.
25. Simmen MW, Leitgeb S, Charlton J, et al. Nonmethylated transposable elements and methylated genes in a chordate genome. Science 1999;283:1164-7.
26. Macleod D, Charlton J, Mullins J, et al. Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev 1994;8:2282-92.
27. Riggs AD, Jones PA. 5-Methylcytosine, gene regulation, and cancer. Adv Cancer Res 1983;40:1-30.
28. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
29. Lapeyre J-N, Becker FF. 5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis ana in carcinomas which result. Biochem Biophys Res Commun 1979;87:698-705.
30. Flatau E, Bogenmann E, Jones PA. Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants. Cancer Res 1983;43:4901-5.
31. Gama-Sosa MA, Slagel VA, Trewyn RW, et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983;11:6883- 94.
32. Goelz SE, Vogelstein B, Hamilton SR, et al. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985;228:187-90.
33. Bariol C, Suter C, Cheong K, et al. The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol 2003;162:1361-71.
34. Ji W, Hernandez R, Zhang XY, et al. DNA demethylation and pericentromeric rearrangements of chromosome 1. Mutat Res 1997;379:33-41.
35. Qu GZ, Grundy PE, Narayan A, et al. Frequent hypomethylation in Wilms tumors of pericentromeric DNA in chromosomes 1 and 16. Cancer Genet Cytogenet 1999;109:34-9.
36. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196:1-7.
37. Suter CM, Martin DI, Ward RL. Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int J Colorectal Dis 2004;19:95-101.
38. Fincham JR, Sastry GR. Controlling elements in maize. Annu Rev Genet 1974;8:15-50.
39. Kashkush K, Feldman M, Levy AA. Transcriptional activation of retrotransposons alters the expression of adjacent genes in wheat. Nat Genet 2003;33:102-6.
40. Oshimo Y, Nakayama H, Ito R, et al. Promoter methylation of cyclin D2 gene in gastric carcinoma. Int J Oncol 2003;23:1663-70.
41. Akiyama Y, Maesawa C, Ogasawara S, et al. Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. Am J Pathol 2003;163:1911-19.
42. Cui H, Onyango P, Brandenburg S, et al. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002;62:6442-6.
43. Cui H, Horon IL, Ohlsson R, et al. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 1998;4:1276-80.
44. Baylin SB, Hoppener JW, de Bustros A, et al. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res 1986;46:2917-22.
45. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
46. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
47. Greger V, Passarge E, Hopping W, et al. Epigenetic changes may contribute to the formation and spontaneous regression or retinoblastoma. Hum Genet 1989;83:155-8.
48. Rainier S, Johnson LA, Dobry CJ, et al. Relaxation of imprinted genes in human cancer. Nature 1993;362:747-9.
49. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 1993;362:749-51.
50. Corn PG, Kuerbitz SJ, van Noesel M, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 1999;59:3352-6.
51. Weber F, Aldred MA, Morrison CD, et al. Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. J Clin Endocrinol Metab 2005;90:1149-55.
52. Esteller M, Sparks A, Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60:4366-71.
53. Kim JC, Koo KH, Roh SA, et al. Genetic and epigenetic changes in the APC gene in sporadic colorectal carcinoma with synchronous adenoma. Int J Colorectal Dis 2003;18:203-9.
54. Bai AHC, long JHM, To K-F, et al. Promoter hypermethylation of tumor-related genes in the progression of colorectal neoplasia. Int J Cancer 2004;112:846-53.
55. Lee S, Hwang KS, Lee HJ, et al. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 2004;84:884-93.
56. Kim HC, Roh SA, Ga IH, et al. CpG island methylation as an early event during adenoma progression in carcinogenesis of sporadic colorectal cancer. J Gastroenterol Hepatol 2005;20:1920-6.
57. Ebert MPA, Mooney SH, Tonnes-Priddy L, et al. Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia 2005;7:771-8.
58. Hibi K, Kodera Y, Ito K, et al. Aberrant methylation of HLTF, SOCS-1, and CDH13 genes is shown in colorectal cancers without lymph node metastasis. Dis Colon Rectum 2005;48:1282-6.
59. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
60. Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst 2001;93:1307-13.
61. Corn PG, Summers MK, Fogt F, et al. Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 2003;24:47-51.
62. Toyota M, Sasaki Y, Satoh A, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 2003;100:7818-23.
63. Maekawa M, Sugano K, Ushiama M, et al. Heterogeneity of DNA methylation status analyzed by bisulfite-PCR-SSCP and correlation with clinico-pathoiogical characteristics in colorectal cancer. Clin Chem Lab Med 2001;39:121-8.
64. Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-Dependent DNA-damage responses. Cell 2005;123:437-48.
65. Young J, Biden KG, Simms LA, et al. HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers. Proc Natl Acad Sci USA 2001;98:265-70.
66. Esteller M, Avizienyte E, Corn PG, et al. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene 2000;19:164-8.
67. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-8.
68. Fox EJ, Leahy DT, Geraghty R, et al. Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer. J Mol Diagn 2006;8:68-75.
69. Wynter CVA, Kambara T, Walsh MD, et al. DNA methylation patterns in adenomas from FAP, multiple adenoma and sporadic colorectal carcinoma patients. Int J Cancer 2006;118:907-15.
70. Nakagawa H, Nuovo GJ, Zervos EE, et al. Age-related hypermethylation of the 5′ region of MLH1 in normal colonie mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001;61:6991-5.
71. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl7 Acad Sci USA 1998;95:6870-5.
72. Miyakura Y, Sugano K, Konishi F, et al. Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology 2001;121:1300-9.
73. Esteller M, Cordon-Cardo C, Corn PG, et al. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 2001;61:2816-21.
74. Shen L, Kondo Y, Hamilton SR, et al. p14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology 2003;124:626-33.
75. Sakamoto N, Terai T, Ajioka Y, et al. Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors. Oncogene 2004;23:8900-7.
76. Oliveira C, Velho S, Domingo E, et al. Concomitant RASSF1A hypermethylation and KRAS//BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene 2005;24:7630-4.
77. Brueckl WM, Grombach J, Wein A, et al. Alterations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) are found frequently in human colorectal tumours displaying either microsatellite stability (MSS) or instability (MSI). Cancer Lett 2005;223:137-42.
78. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16.
79. Frigola J, Song J, Stirzaker C, et al. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006;38:540-9.
80. Peters AHFM, Mermoud JE, O'Carroll D, et al. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nat Genet 2002;30:77-80.
81. Fahrner JA, Eguchi S, Herman JG, et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002;62:7213-18.
82. Kondo Y, Shen L, Issa J-PJ. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 2003;23:206-15.
83. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003;3:89-95.
84. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at lys16 and trimethylation at lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
85. Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004;6:731-40.
86. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006;94:179-83.
87. Ahmad K, Henikoff S. Histone H3 variants specify modes of chromatin assembly. Proc Natl Acad Sci USA 2002;99(Suppl 4):16477-84.
88. Faast R, Thonglairoam V, Schulz TC, et al. Histone variant H2A.Z is required for early mammalian development. Curr Biol 2001;11:1183-7.
89. Raisner RM, Hartley PD, Meneghini MD, et al. Histone variant H2A.Z marks the 5′ ends of both active and inactive genes in euchromatin. Cell 2005;123:233-48.
90. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
91. Jass JR. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol 2005;2:398-405.
92. Sharrard RM, Royds JA, Rogers S, et al. Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br J Cancer 1992;65:667-72.
93. Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998;95:8698-702.
94. Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998;42:673-9.
95. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
96. Oliveira C, Pinto M, Duval A, et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003;22:9192-6.
97. Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209-12.
98. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:191-5.
99. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004;53:1137-44.
100. Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001;61:4689-92.
101. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-6.
102. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002;122:1376-87.
103. van Rijnsoever M, Grieu F, Elsaleh H, et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002;51:797-802.
104. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-45.
105. Ward RL, Cheong K, Ku S-L, et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003;21:3729-36.
106. Yamashita K, Dai T, Dai Y, et al. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 2003;4:121-31.
107. Issa J-P. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-93.
108. Frazier ML, Xi L, Zong J, et al. Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. Cancer Res 2003;63:4805-8.
109. Ward RL, Williams R, Law M, et al. The CpG island methylator phenotype is not associated with a personal or family history of cancer. Cancer Res 2004;64:7618-21.
110. Petko Z, Ghiassi M, Shuber A, et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res 2005;11:1203-9.
111. Nuovo GJ, Nakagawa H, Sotamaa K, et al. Hypermethylation of the MLH1 promoter with concomitant absence of transcript and protein occurs in small patches of crypt cells in unaffected mucosa from sporadic colorectal carcinoma. Diagn Mol Pathol 2006;15:17-23.
112. Kawakami K, Ruszkiewicz A, Bennett G, et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 2006;94:593-8.
113. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
114. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
115. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993;85:875-84.
116. Kim Y-I. Folate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies. Environ Mol Mutagen 2004;44:10-25.
117. Ulrich CM. Nutrigenetics in cancer research - folate metabolism and colorectal cancer. J Nutr 2005;135:2698-702.
118. Pufulete M, Emery PW, Sanders TAB. Folate, DNA methylation and cob-rectal cancer. Proc Nutr Soc 2003;62:437-45.
119. Song J, Medline A, Mason JB, et al. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res 2000;60:5434-40.
120. Giovannucci E, Rimm EB, Ascherio A, et al. Alcohol, low-methionine-low-tolate diets, and risk of colon cancer in men. J Natl Cancer Inst 1995;87:265-73.
121. van Engeland M, Weijenberg MP, Roemen GMJM, et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res 2003;63:3133-7.
122. Waterland RA, Jirtle RL. Transposable elements: Targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003;23:5293-300.
123. Ahuja N, Li Q7 Mohan AL, et al. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998;58:5489-94.
124. Yuasa Y. DNA methylation in cancer and ageing. Mech Ageing Dev 2002;123:1649-54.
125. Feinberg AP. The epigenetics of cancer etiology. Semin Cancer Biol 2004;14:427-32.
126. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-5.
127. Suter CM, Martin DIK, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 2004;36:497-501.
128. Hitchins M, Williams R, Cheong K, et al. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology 2005;129:1392-9.
129. Gazzoli I, Loda M, Garber J, et al. A hereditary nonpolyposis colorectal carcinoma case associated with hypermefhylafion of the MLH1 gene in normal tissue and loss of heterozygosity or the unmethylated allele in the resulting microsatellife instability-high tumor. Cancer Res 2002;62:3925-8.
130. Miyakura Y, Sugano K, Akasu T, et al. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin Gastroenterol Hepatol 2004;2:147-56.
131. Hitchins M, Suter C, Wong J, et al. Germline epimutations of APC are not associated with inherited colorectal polyposis. Gut 2006;55:586-7.
132. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-206.
133. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer [see comments]. Gastroenterology 2004;126:394-401.
134. Benatti P, Gafa R, Barana D, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005;11:8332-40.
135. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instabilily status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
136. van Rijnsoever M, Elsaleh H, Joseph D, et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fiuorouracil in stage III colorectal cancer. Clin Cancer Res 2003;9:2898-903.
137. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006;94:1087-92.
138. McGarvey KM, Fahrner JA, Greene E, et al. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006;66:3541-9.
139. Constantinides PG, Jones PA, Gevers W. Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 1977;267:364-6.
140. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005;97:1498-506.